Table 1

Patient demographics and baseline disease characteristics (N = 25)

CharacteristicNo. of patients% of patients
Age, y   
    Median 14 — 
    Range 1-21 — 
Sex   
    Male 16 64 
    Female 36 
Race   
    Black 
    American Indian or Alaska Native 
    Asian 
    White 12 48 
    Other 32 
Immunophenotype   
    B-precursor 21 84 
    T cell 
    Unknown 12 
Prior regimens   
    Median — 
    Range 1-3 — 
    1 regimen* 16 
    2 regimens 14 56 
    3 regimens 28 
Refractory to immediate prior regimen 15 60 
Performance status (Karnofsky/Lansky)   
    50% 
    60% 
    70% 
    80% 12 
    90% 24 
    100% 10 40 
Prior HSCT 16 
CharacteristicNo. of patients% of patients
Age, y   
    Median 14 — 
    Range 1-21 — 
Sex   
    Male 16 64 
    Female 36 
Race   
    Black 
    American Indian or Alaska Native 
    Asian 
    White 12 48 
    Other 32 
Immunophenotype   
    B-precursor 21 84 
    T cell 
    Unknown 12 
Prior regimens   
    Median — 
    Range 1-3 — 
    1 regimen* 16 
    2 regimens 14 56 
    3 regimens 28 
Refractory to immediate prior regimen 15 60 
Performance status (Karnofsky/Lansky)   
    50% 
    60% 
    70% 
    80% 12 
    90% 24 
    100% 10 40 
Prior HSCT 16 

— indicates not applicable.

*

Primary refractory (n = 2); 1 patient with first DOR, 31.9 weeks; and 1 patient with first DOR, 206 weeks.

These 4 patients were enrolled before a protocol amendment excluding patients with prior HSCT.

Close Modal

or Create an Account

Close Modal
Close Modal